Key result
In patients with hypoxic COPD, infusion of atrial natriuretic peptide selectively reduced right ventricular afterload, lowering mean pulmonary artery pressure from 28.7 to 25.9 mm Hg.
Why the study?
Does atrial natriuretic peptide infusion reduce pulmonary pressures in patients with hypoxic COPD?
Does atrial natriuretic peptide infusion reduce pulmonary pressures in patients with hypoxic COPD?
ANP infusion selectively reduces right ventricular afterload in patients with hypoxic COPD, suggesting a physiological role in protecting the pulmonary circulation from pressure overload.
Answers are grounded in this paper and cite their sources.
ANP infusion lowers pulmonary pressure in hypoxic COPD; leaves open whether endogenous ANP protects the circulation or offers therapy.
BACKGROUND: Pulmonary artery pressure is elevated in patients with advanced chronic obstructive pulmonary disease (COPD). Release of atrial natriuretic peptide (ANP) is increased in pulmonary hypertension and this hormone may both selectively vasodilate pulmonary vessels and inhibit pulmonary vascular remodelling. The hypothesis that ANP has a physiological role in protection of the pulmonary circulation from pressure overload, and that it may be beneficial in patients with COPD, has been examined. METHODS: Ten patients with hypoxic COPD were infused for 30 minute periods with saline followed by ANP at 0.4, 2, and 10 pmol/kg/min respectively via a pulmonary artery catheter whilst monitoring haemodynamics and oxygenation. RESULTS: Levels of immunoreactive ANP (irANP) increased from a mean (SD) of 23 (15) pmol/l to a maximum of 94 (41) pmol/l. Neither systemic blood pressure, cardiac output nor total systemic vascular resistance showed any correlation with irANP levels. There were negative correlations between levels of ANP and mean pulmonary artery pressure which fell from 28.7 to 25.9 mm Hg, pulmonary artery wedge pressure which fell from 6.5 to 4.6 mmHg, and total pulmonary vascular resistance which fell from 489 to 428 dynes s cm-5. There was a small fall in PaCO2 from 6.2 to 5.9 kPa, whilst venous admixture and oxygen delivery both increased non-significantly. CONCLUSIONS: At these pathophysiological concentrations there was evidence that ANP selectively reduced right ventricular afterload. These data support the hypotheses that increased plasma levels of ANP may be beneficial in hypoxic COPD, and that endogenous ANP may ameliorate pulmonary hypertension in humans.
No takes yet. Share an insight, caveat, or question.
Rogers et al. (1994) studied Hypoxic chronic obstructive pulmonary disease (COPD) (n=10). Atrial natriuretic peptide (ANP) vs. Saline was evaluated on Mean pulmonary artery pressure. In patients with hypoxic COPD, infusion of atrial natriuretic peptide selectively reduced right ventricular afterload, lowering mean pulmonary artery pressure from 28.7 to 25.9 mm Hg.
Synapse has enriched 10 related papers. Consider them for comparative context: